Table 1.
Baseline characteristics of study participants (safety population)
| Characteristic | Placebo (n = 101) | Albiglutide 30 mg weekly (n = 101) | Albiglutide 50 mg weekly (n = 99) |
|---|---|---|---|
| Age (years) | 53.1 ± 11.7 | 53.6 ± 10.9 | 52.0 ± 11.8 |
| Sex, male | 58 (57.4) | 58 (57.4) | 50 (50.5) |
| Weight (kg) | 95.4 ± 19.9 | 95.8 ± 19.6 | 97.10 ± 17.8 |
| BMI (kg/m2) | 33.00 ± 5.4 | 33.7 ± 5.1 | 33.9 ± 5.5 |
| Baseline HbA1c (%) | 8.0 ± 0.9 | 8.0 ± 0.8 | 8.2 ± 0.9 |
| Baseline HbA1c (mmol/mol) | 64.2 ± 9.9 | 64.5 ± 9.5 | 66.2 ± 10.3 |
| Duration of diabetes (years) | 4.3 ± 4.0 | 3.4 ± 3.7 | 4.2 ± 4.6 |
| Prior MI | 4 (4.0) | 3 (3.0) | 2 (2.0) |
| Race | |||
| White | 79 (78.2) | 85 (84.2) | 78 (78.8) |
| African-American/African | 14 (13.9) | 10 (9.9) | 14 (14.1) |
| Asian | 5 (5.0) | 1 (1.0) | 1 (1.0) |
| Ethnicity | |||
| Hispanic/Latino | 29 (28.7) | 30 (29.7) | 26 (26.3) |
Data are mean ± SD or n (%)